TT 10

Drug Profile

TT 10

Alternative Names: Autologous EBV specific Cytotoxic T Lymphocytes - Tessa Therapeutics; EB-VST - Tessa Therapeutics; Epstein-Barr virus specific autologous cytotoxic T-lymphocytes therapy - Tessa Therapeutics; Epstein-Barr virus specific T cells - Tessa Therapeutics; TT10; TT10-EB VST

Latest Information Update: 11 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Centre (Singapore)
  • Developer National Cancer Centre (Singapore); Tessa Therapeutics
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Nasopharyngeal cancer
  • Preclinical Gastric cancer

Most Recent Events

  • 30 Sep 2015 TT 10 receives Fast track status from the US FDA for EBV-positive Head and neck cancers, including nasopharyngeal carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top